Interestingly, studies have shown that antibiotic treatment during anti-PD-1/PD-L1 therapy or combined anti-CTLA-4 and PD-1/PD-L1 therapy in advanced esophagogastric cancer did not result in the adverse effects commonly seen in cases of lung cancer, renal cancer, or melanoma [16,17]. The gene discussed is CD274; the disease is lung carcinoma.